Login Preferences
About News Publications Statistics Downloads API Guide License How to use Preferences
bn:02615279n
Noun Concept
Categories: Drugs not assigned an ATC code, Experimental cancer drugs, Ureas, Tyrosine kinase inhibitors, Antineoplastic and immunomodulating drug stubs
EN
linifanib  1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea  ABT-869  ABT869  ABT 869
EN
Linifanib is a structurally novel, potent inhibitor of receptor tyrosine kinases, vascular endothelial growth factor and platelet-derived growth factor with IC50 of 0.2, 2, 4, and 7 nM for human endothelial cells, PDGF receptor beta, KDR, and colony stimulating factor 1 receptor, respectively. Wikipedia
Definitions
Relations
Sources
EN
Linifanib is a structurally novel, potent inhibitor of receptor tyrosine kinases, vascular endothelial growth factor and platelet-derived growth factor with IC50 of 0.2, 2, 4, and 7 nM for human endothelial cells, PDGF receptor beta, KDR, and colony stimulating factor 1 receptor, respectively. Wikipedia
An inhibitor of certain receptor tyrosine kinases, vascular endothelial growth factor, and platelet-derived growth factor. Wiktionary
IS A
compound
enzyme inhibitor
PHYSICALLY INTERACTS WITH
RET proto-oncogene
KIT
Wikipedia
EN
linifanib
Wikidata
EN
linifanib
Wiktionary
EN
linifanib
Wikipedia Redirections
EN
ABT-869
Wikidata Alias
EN
ABT-869, ABT869, ABT 869, AL-39324, RG-3635, 1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea, N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N'-(2-fluoro-5-methylphenyl)urea

Please note that, in order to improve your browsing experience on this website, BabelNet® uses various types of cookies, including: browsing functionality, performance and statistical cookies.

By continuing to browse the site you are agreeing to our use of cookies. OK

License